SCHEMBL6299750

SCHEMBL6299750

CSc1ccc(Cn2c(C)nc3c(C)cc(C(=O)NS(=O)(=O)c4ccc(C)cc4)nc32)c(Cl)c1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 5/20 0.40
FLT1 P17948 3/20 0.40
FLT4 P35916 3/20 0.40
KDR P35968 3/20 0.40
PTGS1 P23219 2/20 0.40
EGFR P00533 3/20 0.39
ALDH1A1 P00352 2/20 0.39
NPC1 O15118 1/20 0.39
MAPT P10636 1/20 0.39
ALKBH2 Q6NS38 1/20 0.36
ALKBH5 Q6P6C2 1/20 0.36
ALKBH3 Q96Q83 1/20 0.36
FTO Q9C0B1 1/20 0.36
POLB P06746 1/20 0.36
HPGD P15428 1/20 0.36
PPARG P37231 1/20 0.34
TP53 P04637 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6298633 0.88 FLT1 (0.42) PTGS2FLT1FLT4KDRPTGS1
SCHEMBL6299198 0.87 PTGS2 (0.43) PTGS2FLT1FLT4KDRPTGS1
SCHEMBL6299197 0.87 FLT1 (0.41) PTGS2FLT1FLT4KDRPTGS1
SCHEMBL6493067 0.87 PTGS2 (0.41) PTGS2FLT1FLT4KDRPTGS1
SCHEMBL6135088 0.87 PTGS2 (0.41) PTGS2FLT1FLT4KDRPTGS1
SCHEMBL6299098 0.86 PPARG (0.44) PTGS2FLT1FLT4KDRPTGS1
SCHEMBL6135191 0.86 FLT1 (0.43) PTGS2FLT1FLT4KDRPTGS1
SCHEMBL6134706 0.85 PTGS2 (0.39) PTGS2FLT1FLT4KDRPTGS1
SCHEMBL6306800 0.85 PTGS2 (0.38) PTGS2FLT1FLT4KDRPTGS1
SCHEMBL6492466 0.85 PTGS2 (0.39) PTGS2FLT1FLT4KDRPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6911469-B2 Sulfonamide compounds and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-06-28 US disclosed
US-20040180947-A1 hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-09-16 US disclosed
US-20020099212-A1 For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-07-25 US disclosed
US-6348474-B1 COMPOUNDS AS ANTIDIABETIC AGENTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-02-19 US disclosed
EP-0995742-A1 SULFONAMIDE COMPOUNDS AND MEDICINAL USE THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-04-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099212-A1 For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity PDE2A, PDE3A, PDE12 PTGS2 584/4885FLT1 858/4885FLT4 1478/4885
US-20040180947-A1 hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications PDE2A, PDE3A, PYGM PTGS2 355/4885FLT1 3426/4885FLT4 3482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.